Predictors of response and survival in cemiplimab-treated cutaneous squamous cell carcinoma: multicenter real-world evidence from Germany.

ABSTRACT:

Purpose

To assess the association of systemic immune-inflammation biomarkers (SIIBs) and other clinical parameters with objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease-specific survival (DSS), and immune-related adverse events (irAEs) in patients with advanced cSCC treated with cemiplimab, and to compare baseline SIIBs levels between early-stage and advanced-stage disease.

Methods

A retrospective multicenter cohort of 110 immunocompetent advanced cSCC patients treated with cemiplimab was analysed. ORR was assessed using logistic regression; PFS and OS were evaluated using Cox models, and DSS using cause-specific hazards. ROC analyses assessed biomarker discrimination. Baseline SIIBs (LMR, NLR, SIRI) were compared between early-s

SUBMITTER: Gambichler T 

PROVIDER: S-EPMC12936293 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature